Navigation Links
Anthera Pharmaceuticals Announces Exercise in Full of Over-Allotment Option and Completion of Public Offering of Common Stock
Date:7/24/2012

HAYWARD, Calif., July 24, 2012 /PRNewswire/ -- Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH), today announced that it has completed the previously announced underwritten public offering of 33,000,000 shares of its common stock, offered at a price to the public of $1.00 per share.  In addition, the Company has sold 4,950,000 shares of its common stock at a price to the public of $1.00 per share pursuant to the underwriters' option to purchase additional shares, resulting in a total public offering of 37,950,000 shares.  The gross proceeds to the Company from the sale of shares in this offering, before deducting customary underwriting discounts and commissions, were $37,950,000.  Anthera intends to use the net proceeds from this offering for general corporate purposes.

Piper Jaffray & Co. and Leerink Swann LLC acted as joint book-running managers in the offering. Canaccord Genuity acted as lead manager in the offering.  Summer Street Research Partners acted as co-manager in the offering.  

The securities described above were offered by the Company pursuant to a shelf registration statement previously filed with, and declared effective by, the Securities and Exchange Commission (the "SEC").  A final prospectus supplement relating to the offering was filed with the SEC and is available on the SEC's website at http://www.sec.gov.  Copies of the final prospectus supplement relating to these securities may be obtained from Piper Jaffray & Co., Attention: Prospectus Department, 800 Nicollet Mall, J12S03, Minneapolis, MN 55402 or by telephone at 800-747-3924 or by email at prospectus@pjc.com, or from Leerink Swann LLC, Attention: Syndicate Department, One Federal Street, 37th Floor, Boston, MA 02110 or by telephone at 800-808-7525 or by email at Syndicate@Leerink.com.   

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of, these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction.

About Anthera Pharmaceuticals

Anthera Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing products to treat serious diseases associated with inflammation and autoimmune diseases.

Safe Harbor Statement

Any statements contained in this press release that refer to future events or other non-historical matters, including statements that are preceded by, followed by, or that include such words as "estimate," "intend," "anticipate," "believe," "plan," "goal," "expect," "project," or similar statements, are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.  These include, but are not limited to, statements relating to the anticipated use of proceeds from the offering.  Such statements are based on Anthera's expectations as of the date of this press release and are subject to certain risks and uncertainties that could cause actual results to differ materially, including but not limited to the risks and uncertainties set forth in Anthera's public filings with the SEC, including Anthera's Annual Report on Form 10-K for the year ended December 31, 2011 and Quarterly Report on Form 10-Q for the quarter ended March 31, 2012.  Anthera disclaims any intent or obligation to update any forward-looking statements, whether because of new information, future events or otherwise, except as required by applicable law.

CONTACT: Bianca Nery of Anthera Pharmaceuticals, Inc., bnery@anthera.com or 510.856.5586.


'/>"/>
SOURCE Anthera Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Anthera Announces the Completion of Patient Dosing in Phase 2b PEARL-SC Study
2. Anthera Announces First Quarter 2012 Financial Report and Conference Call
3. Anthera Pharmaceuticals Reports 2012 First Quarter Financial Results And Provides Clinical Progress Update
4. Anthera Updates Phase 3 Plans Following Results from the Phase 2b PEARL-SC Dose Ranging Study of Blisibimod
5. Anthera Pharmaceuticals to Present at the 7th Annual JMP Securities Healthcare Conference
6. Anthera Pharmaceuticals Provides Additional Data from the Recently Completed PEARL-SC Study of Blisibimod in the Proposed Phase 3 Population
7. Anthera Pharmaceuticals Announces Proposed Public Offering of Common Stock
8. Anthera Pharmaceuticals Announces Pricing of Public Offering of Common Stock
9. Savient Pharmaceuticals to Hold First Quarter 2012 Financial Results Conference Call on Wednesday, May 9, 2012
10. Auxilium Pharmaceuticals to Present at the Deutsche Bank 37th Annual Healthcare Conference
11. Nouveau Life Pharmaceuticals (HRID) Contracts with U.S. Manufacturer to Produce New Female Supplement
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2017)... of Echenberg Institute, is announcing a new safe and effective at-home VuVa ... other painful pelvic pain conditions such as pelvic floor dysfunction, vulvodynia, vulvar ... ... VuVa ... company, VuVatech LLC, fills a void in the women,s wellness market because ...
(Date:7/10/2017)... , July 10, 2017  US medical equipment ... in 2021, according to Medical Equipment & ... by Freedonia Focus Reports. Continued increases in demand for ... aging of the population and supported by gains in ... equipment and supplies. New product introductions will also drive ...
(Date:7/10/2017)... S.C. , July 10, 2017  BDI ... purchasing and patient support services organization serving specialty ... today the launch of four significant, value-added member ... market insights, better manage reimbursement and improve access ... and factor therapies. ...
Breaking Medicine Technology:
(Date:7/27/2017)... ... July 28, 2017 , ... ... upcoming episode of the award-winning television series, American Famer, scheduled to broadcast fourth ... , Syngenta is dedicated to helping humanity face its toughest challenge: how to ...
(Date:7/27/2017)... ... July 27, 2017 , ... MEDsys Software Solutions, the ... Care Organizations and Home Care Agencies, has been awarded CIO Applications Magazine’s Top ... solutions to over 1,000 agencies and multiple State Medicaid and Managed Care Programs. ...
(Date:7/27/2017)... ... July 27, 2017 , ... GAFFEY Healthcare, a leading provider ... Clinkscales to Vice President of Revenue Cycle Business Services and Suzanne Dusak to ... chief executive officer (CEO). , Elrene has been with company since Oct 2014 ...
(Date:7/27/2017)... ... 27, 2017 , ... Healthy eating isn’t always easy. Currently, more than 80 percent of Americans ... Americans overeat refined grains and sugar. This trend may help explain why the obesity rate ... are obese. , As a culture, we seem to have food on the brain more. ...
(Date:7/27/2017)... ... July 27, 2017 , ... ... compete to form startup companies around 117 breakthrough inventions from 55 institutions, including ... Institute, and National Institute of Biomedical Imaging and Bioengineering), the United States Army, ...
Breaking Medicine News(10 mins):